Drug combo slows biliary tract cancer but does not extend survival
Adding a new drug, tovecimig, to paclitaxel helped more patients with advanced biliary tract cancer in a trial. Tumors responded in 18% of patients, against 5.3% on paclitaxel alone. The cancer also took longer to grow. But patients on the combination did not live longer. The results were presented at a cancer meeting in Madrid.
Where this came from. One outlet reported this. We read it, then wrote the sixty words above.